Evidence map›Paper›PMID 20463812›Full record

Trial reportPLoS pathogens2010

Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa.

Thilo Köhler, Gabriel G Perron, Angus Buckling, Christian van Delden

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in PLoS pathogens, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
89citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 169 citations in OpenAlex.

  1. Pooled it
  2. Macrolide antibiotics for bronchiectasis.The Cochrane database of systematic reviews · 2018
    Pooled it
  3. Trial
  4. Mechanisms ofMedicina (Kaunas, Lithuania) · 2026
    Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Antibiotic-ResistantMicroorganisms · 2025
    Review
  11. Article
  12. Parallel ecological and evolutionary responses to selection in a natural bacterial community.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  13. Review
  14. Observational
  15. Anti-Microorganisms · 2023
    Review
  16. Spiramycin DisarmsAntibiotics (Basel, Switzerland) · 2023
    Article
  17. Article
  18. Review
  19. Article
  20. Article

29 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Thilo KöhlerService of Infectious Diseases, University Hospital Geneva and Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland.
Gabriel G Perron
Angus Buckling
Christian van Delden
University of Geneva · CHUniversity of Oxford · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rising development of bacterial resistance the search for new medical treatments beyond conventional antimicrobials has become a key aim of public health research. Possible innovative strategies include the inhibition of bacterial virulence. However, consideration must be given to the evolutionary and environmental consequences of such new interventions. Virulence and cooperative social behaviour of the bacterium Pseudomonas aeruginosa rely on the quorum-sensing (QS) controlled production of extracellular products (public goods). Hence QS is an attractive target for anti-virulence interventions. During colonization, non-cooperating (and hence less virulent) P. aeruginosa QS-mutants, benefiting from public goods provided by wild type isolates, naturally increase in frequency providing a relative protection from invasive infection. We hypothesized that inhibition of QS-mediated gene expression removes this growth advantage and selection of less virulent QS-mutants, and maintains the predominance of more virulent QS-wild type bacteria. We addressed this possibility in a placebo-controlled trial investigating the anti-QS properties of azithromycin, a macrolide antibiotic devoid of bactericidal activity on P. aeruginosa, but interfering with QS, in intubated patients colonized by P. aeruginosa. In the absence of azithromycin, non-cooperating (and hence less virulent) lasR (QS)-mutants increased in frequency over time. Azithromycin significantly reduced QS-gene expression measured directly in tracheal aspirates. Concomitantly the advantage of lasR-mutants was lost and virulent wild-type isolates predominated during azithromycin treatment. We confirmed these results in vitro with fitness and invasion experiments. Azithromycin reduced growth rate of the wild-type, but not of the lasR-mutant. Furthermore, the lasR-mutant efficiently invaded wild-type populations in the absence, but not in the presence of azithromycin. These in vivo and in vitro results demonstrate that anti-virulence interventions based on QS-blockade diminish natural selection towards reduced virulence and therefore may increase the prevalence of more virulent genotypes in the Hospital environment. More generally, the impact of intervention on the evolution of virulence of pathogenic bacteria should be assessed.

Indexed as

Pseudomonas aeruginosaAnti-Bacterial AgentsAzithromycinCritical IllnessDrug Resistance, BacterialEvolution, MolecularHumansMutationPlacebosPneumonia, BacterialPseudomonas InfectionsQuorum SensingRespiration, ArtificialTracheaVirulenceAnti-Bacterial AgentsAzithromycinPlacebos

Identifiers

PMID20463812
PMCPMC2865528
OpenAlexW2008679353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.